<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0067">
 <label>67.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Scaldaferri</surname>
    <given-names>F</given-names>
   </name>, 
   <name name-style="western">
    <surname>Pugliese</surname>
    <given-names>D</given-names>
   </name>, 
   <name name-style="western">
    <surname>Privitera</surname>
    <given-names>G</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: reorganisational response in a high-volume Italian inflammatory bowel disease centre</article-title>. 
  <source>United European Gastroenterol J.</source>
  <year>2020</year>. doi: 
  <pub-id pub-id-type="doi">10.1177/2050640620929133</pub-id>. Accessed May 7, 2020.
 </mixed-citation>
</ref>
